(IN BRIEF) GSK has announced that momelotinib, a differentiated JAK inhibitor marketed as Ojjaara or Omjjara in approved indications, has received orphan drug designations from the US Food and Drug Administration and the European Medicines Agency for the treatment of … Read the full press release →
Posted in Business, European Union, Government, Healthcare, Law, Pharma & Biotech, Science, Technology, United Kingdom
Tagged activin A receptor type I, ACVR1, anaemia, ATLAS trial, bone marrow failure, clinical trial, clonal myeloid disorder, EHA Congress, EMA, European Hematology Association Congress, European Medicines Agency, FDA, GSK, GSK Advances Momelotinib Development Programme With Orphan Drug Designations for VEXAS Syndrome, GSK’s Momelotinib Receives US and EU Orphan Drug Designations for Rare VEXAS Syndrome, haemato-inflammatory condition, haematologic features, haematologic malignancy, hepcidin, JAK inhibitor, JAK1, JAK2, Janus kinase 1, Janus kinase 2, life-threatening disease, lung involvement, macrocytic anaemia, momelotinib, Momelotinib Gains Regulatory Support in US and EU as GSK Targets High Unmet Need in VEXAS Syndrome, myelofibrosis, neutrophilic dermatosis, ODD, Ojjaara, Omjjara, orphan drug designation, phase II/III trial, rare disease, rare disorder treatment, regulatory submissions, relapsing chondritis, rheumatologic features, splenomegaly, thrombocytopenia, UBA1 gene mutation, US Food and Drug Administration, uveitis, Vacuoles E1 enzyme X-linked Autoinflammatory Somatic syndrome, vasculitis, VEXAS syndrome
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
